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Introduction
The medical nutrition therapy of a patient with diabetes mellitus 
(DM) poses many challenges to the health care provider. In order to 
reach the goals of treatment, careful consideration of the different 
treatment options needs to be investigated.
The goals of nutritional therapy for DM include the maintenance of 
as near-normal blood glucose levels as possible, the achievement of 
optimal blood lipid levels, the prevention and treatment of acute and 
chronic complications of diabetes; while concurrently maintaining 
fluid balance in a patient receiving nutritional support.1,2 Another 
important factor in the nutritional management of a diabetic patient 
is glycaemic control during enteral feeding since hyperglycaemia 
has been associated with an increased risk for infection in patients 
with DM and in ICU patients in general.2,3 Current guidelines for 
blood glucose control in critically ill patients with and without 
DM, recommend keeping glucose values in the range of 6,1–8,3 
mmol/L.3,4 There is a higher incidence of severe hypoglycaemia in 
patients treated to tighter limits when blood glucose is maintained 
between 4.5 and 6.1 mmol/L.4
Diet composition
The ideal composition of the diabetic diet, specifically with regards 
to the carbohydrate and fat content, has received much attention 
and research in the last 15 years. From a high carbohydrate, low 
fat diet to a low carbohydrate, high fat diet, to a mixture of both. 
What has become more evident with time is that it is not only the 
total amounts, but rather the type of carbohydrate and fat that is 
important.1
The nutritional recommendations for individuals with DM of the 
American Diabetes Association for instance (Table I) indicate 
that in the 1990’s, the recommended contribution to total energy 
(TE) of carbohydrate was 50–60%, fat had to be < 30% and no 
recommendations were made for glycaemic index (GI).5 About 10–
12 years later, the recommendations changed to the combination 
of carbohydrate and fat, especially monounsaturated fat (MUFA), 
contributing between 60–70% total energy, saturated fat < 7%, 
poly-unsaturated fat < 10%, trans fatty acids as low as possible 
and cholesterol < 300 ml per day. Still no GI recommendation was 
included.6 From 2006 up to the present, no specific percentage 
recommendations are made for the percentage contribution of 
carbohydrate and fat in terms of total energy, but carbohydrate 
should be > 130 g per day, saturated fat < 7%, trans fatty acids 
as low as possible and cholesterol < 200 ml per day. Fibre intake 
should be 14 g/1000 kcal, with emphasis on low GI foods.1,3
The emphasis that was placed on increasing fat, especially MUFA, 
stemmed from research associating hypertriglyceridaemia with 
diets high in carbohydrate.7 By decreasing the carbohydrate 
contribution and simultaneously increasing the fat contribution, 
especially MUFA, a positive outcome on lipid management, together 
with glucose control was found and this contributed to the changed 
recommendations. It was then thought that these high fat diets could 
result in weight gain, but studies proved that increased MUFA diets 
as part of an energy-controlled diet plan, would not result in weight 
gain.2 The most recent guidelines take emphasis away from specific 
percentage contributions of carbohydrate and fat, and make room 
for a more individualised approach, but they do indicate minimum 
carbohydrate and maximum saturated fat intake. Also, current 
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recommendations define better the amount of fibre and place 
emphasis specifically on GI.
It is therefore to be noted that the composition of enteral 
formulae specific for the management of DM reflect the 
prevailing recommendations at the time a given formula became 
available. The majority of enteral nutrition products for DM have a 
carbohydrate content of 30–45% and fat between 40–49%, mainly 
monounsaturated fat, with a mix of soluble and insoluble fibre (total 
of 14–24 g/l). Does this composition of such products have short- 
and long-term benefits for the patient and which component is 
crucial for the outcome or is it the combination that really matters? 
The role of fibre
Fibre is advantageous to the diabetic patient not only because it helps 
against constipation (insoluble fibre),8,9 but also because it is known 
to decrease blood glucose and lipid levels (mainly soluble fibre).8,9 
This is achieved by the ability of fibre to regulate the absorption of 
glucose through reducing the rate of digestion and prolonging gastric 
emptying, thereby improving postprandrial blood glucose control.10 
The recommended fibre intake varies from 20–50 grams per day, or 
14–25 g/1000 kcal (4200 kJ) and about 50% of fibre should be of 
the soluble type.1,7,10 An adequate fluid intake is essential in patients 
receiving fibre-containing enteral nutrition, especially if long-term, to 
prevent constipation.11
Fibre supplementation of enteral nutrition is normally done in order 
to attempt to improve GIT tolerance i.e. improve diarrhoea; prevent 
constipation and improve glycaemic control.8,12
Elia et al13 performed a systematic review and meta-analysis 
to determine the clinical significance of fibre-containing enteral 
formulae. They included 51 studies that met their inclusion criteria. 
The type of fibre used most in the studies was soy polysaccharides, 
followed by a fibre-mix of soluble and insoluble fibres or by other 
individual fibre components. In the hospitalised patients, fibre-
containing feeds were well tolerated and resulted in improvements 
in clinical outcomes. The overall incidence of diarrhoea was 
significantly reduced by 32% (OR = 0,68, p = 0,03). The effect was 
most pronounced in those with a high incidence of diarrhoea at 
initiation of the formula. Due to heterogeneity between the studies, 
especially between the ICU studies, results should be interpreted 
according to ICU and non-ICU patient populations. In the ICU group, 
the incidence of diarrhoea was reduced by only 2% (OR = 0,98), but 
in the non-ICU group it was reduced by 58% (OR = 0,42, p = 0,001). 
This highlights the importance of group-specific analysis of data. 
The amount of fibre consumed in the studies ranged from 
14–34,9 g/day and did not show a significant relationship with 
the diarrhoea incidence.13 The fibre intake did, however, show a 
significant positive relationship with faecal mass. The latter did not 
directly affect the prevalence of constipation, since even though the 
fibre-containing feeds resulted in less patients reporting constipation, 
the results were not significant. Bowel frequency was increased by 
fibre supplementation in patients with a low frequency at baseline 
and vice versa, with little effect on patients with a normal bowel 
frequency.13
When assessing outcomes of fibre-supplemented formulae versus 
an enhanced fibre intake in the diet, it should be remembered that 
modified fibres are being used in formulae in order to reduce the 
occurrence of blockage of feeding tubes. This might affect the 
metabolic pathways and water-holding properties of the fibre that 
could explain the differences in outcomes.13 Also, assessing formulae 
using a single fibre source with those using fibre mixtures will also 
be expected to affect the outcome.
Carbohydrate and fat contribution to total energy
Some clinical studies have indicated that high carbohydrate (> 55%), 
low fat (< 30%) diets resulted in increased postprandrial plasma 
glucose and hypertriglyceridaemia as compared to lower carbohydrate 
(40–45%) and higher fat (45%), specifically monounsaturated fat 
(20–25%) diets.1,7 The latter diet composition did not only result 
in better glucose control, but the lipid abnormalities were also 
improved. Other researchers found similar results, but additionally 
reported the total energy intake of the diet to be the deciding factor. 
In patients receiving reduced energy intake, high carbohydrate diets 
did not increase triglyceride levels. This was only found when a high 
energy intake was maintained. Because of the individual response 
to high carbohydrate diets, it is recommended that individual dietary 
adaptations should be made regarding the carbohydrate and fat 
composition in the diet of a given patient. Other researchers have 
reported that replacing saturated fats with polyunsaturated fat had 
similar results to replacing saturated fat with monounsaturated fats. 
Depending on the total energy and carbohydrate intake, as well as 
the individual response to the diet, saturated fat can therefore be 
replaced by either unsaturated fatty acid or carbohydrate.1,2,7
Table I: Adaptations in the nutritional recommendations of the American Diabetes Association 1994–2006
Year Carbohydrate Fibre Glycaemic index Fat
19945 50–60% TE Consume a variety of foods No recommendation
TF < 30% TE
SF < 10% TE
20046 CHO + MUFA = 60–70% TE Similar to general public No recommendation
SF < 7% TE
TFA minimum
PUFA < 10% TE
Chol < 300 mg
20061
CHO > 130 g per day
14 g/1000 kcal Emphasis on low GI foods
SF < 7% TE
TFA minimum
Chol < 200 mg
TE = total energy; CHO = carbohydrate; GI = glycaemic index; TF = total fat; SF = saturated fat; MUFA = monounsaturated fat; PUFA = poly-unsaturated fat; Chol = cholesterol; TFA = trans fatty acids
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Studies comparing diabetes-specific formulae with standard 
formulae have reported a neutral effect on glucose control and lipid 
management14; a reduction in peak glucose values15,16,17; a reduced 
HbA1c profile15,16; lower postprandial glucose values18; reduced 
insulin requirements16 and no significant effect on lipid values.14,16,18 
Unfortunately, due to relatively small patient numbers and short 
duration of studies, as well as different feed compositions, it is 
difficult to compare results and to determine the clinical impact of 
the outcomes.
Elia et al19 performed a systematic review and meta-analysis to 
determine the benefits of enteral nutrition support, specifically the 
use of diabetes-specific formulae for patients with DM. In total 
23 studies were included of which 19 were RCT and the majority 
studied type 2 DM. Due to different study methodologies, relatively 
small numbers of studies were grouped together for subgroup 
analysis. Compared to standard formulae, DM specific formulae 
Studies comparing diabetes-specific formula with standard formula 
resulted in significantly lower postprandrial blood glucose rise (by 
1,03 mmol/L), significantly smaller area under the curve (AUC) and 
insulin AUC values, and reductions in A1c by 0,6%. The effects on the 
blood lipid profile were less pronounced with no significant effects 
on cholesterol, LDL, HDL and triglyceride values. Also of importance 
was the finding that no significant differences in complication rates 
were reported. The authors concluded that DM specific formulae can 
result in improvements on blood glucose control.19
Conclusion
Do we really need specialised formulae for diabetes patients or can 
the patients be treated just as effectively with a standard polymeric 
formula with or without fibre? According to the ADA,3 various studies 
have attempted to identify the ideal mix of macronutrients for patients 
with DM. It is unlikely that one such combination of macronutrients 
exists and therefore emphasis should be placed in individualised 
approaches.1,3 
The majority of diabetes-specific enteral formulae on the market in 
South Africa contain a combination of different fibres, with an altered 
carbohydrate to fat ratio with emphasis on MUFA. The question can 
thus be asked which of these two main alterations i.e. addition 
of fibre or carbohydrate to fat manipulation is the most important 
and successful, or is it the combination of the two that is of the 
essence?
In all patients, fermentable fibres are effective for glucose 
control.8,9 Since the dyslipidaemia of diabetes (type 2), especially 
hypertriglyceridaemia, is often disproportionate to the degree of 
hyperglycaemia, the latter needs to be monitored and treated 
individually.2 Both manipulations of DM-specific enteral formula, i.e. 
addition of fibre and altered carbohydrate to fat percentage does not 
show convincing evidence regarding lipid management.2,19 
In the critically ill patient in an ICU setting, the tolerance of fibre 
sources is dependent on the function of the gastro-intestinal tract 
and the use of fibre (quantity and type) should be reconsidered 
based on the given clinical setting. Patients at high risk of bowel 
dysmotility and hypotensive patients at risk of developing bowel 
ischaemia should not receive any fibre, especially insoluble fibre.4,16 
Since bowel dysmotility is present in a great number of ICU patients, 
the use of most fibre-containing feeds would not be indicated. 
In the non-ICU patient population in a general ward or in the 
long-term home enterally supported patient the scenario can be 
totally different. Diarrhoea and/or constipation are probably the 
most commonly encountered complications in these cases. Fibre 
containing feeds have been shown to be effective in the management 
of both extremes of stool adaptations and therefore have a definite 
role to play.8 To prevent and manage diarrhoea, soluble fibre should 
be administered and to prevent and manage constipation, a mixture 
of soluble and insoluble fibre is recommended.8,9 In the DM patient 
with gastroparesis, fibre blends, especially insoluble fibre, is not very 
practical11 and a high fat intake which normally may have beneficial 
outcomes on glucose management due to slowing down of gastric 
emptying, will also worsen the gastroparesis.20
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